FILTER
FILTERED ARTICLE RESULTS
Presas de Relaves: La Prevención de Fallas Catastróficas y los Principios ESG
July 14, 2022
Guillermo Barreda, General Manager, Knight Piésold Peru
Logistics Challenges in 2021
August 27, 2021
How logistics specialists are dealing with global supply chain disruptions that have no near-term solution.
Industry Thoughts on Latin American Logistics
August 27, 2021
International logistics providers have their say on supply chain disruptions.
Sustainability in Mining
August 06, 2021
More than a buzzword, ESG has become the overarching theme impacting all facets of mining.
The Global Tailings Standard
April 16, 2021
The mining industry and investment community are collaborating to mitigate a perpetual risk, after a series of high-profile disasters.
Tailings Management
April 16, 2021
Expert Opinion Article by Dan Etheredge, General Manager, Klohn Crippen Berger S.A.
Optimism Returns to Peru’s Mining Sector
March 21, 2021
Surging copper brings renewed optimism to Peru, but a pivotal election looms.
Mining Production in Peru
October 02, 2020
Peru’s mines are making up for the time lost during lockdown.
Managing The Social Aspect
June 04, 2020
Social tensions must be eased to expedite project development in Peru.
Mining in the Shadow of COVID-19
May 12, 2020
Peru acts quickly as the COVID-19 pandemic devastates global economies.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENTLY PUBLISHED
United States Life Sciences 2023
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
